Skip to content

A verification study on improvements in the immune system and defecation: A randomized open-label trial

A verification study on improvements in the immune system and defecation: A randomized open-label trial - A verification study on improvements in the immune system and defecation

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000028269
Enrollment
90
Registered
2017-07-18
Start date
2017-03-18
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Japanese adults who are healthy or regularly see a doctor

Interventions

Duration: 4 weeks Test Material: Probiotic food (high dose) Dosage: Take 1 pack, three times a day after each meal Duration: 4 weeks Test Material: Probiotic food (low dose) Dosage: Take 1 pack, o

Sponsors

ORTHOMEDICO Inc.
Lead Sponsor
Medical Corporation Seishinkai, Takara Clinic.
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Sixty-five years and more Japanese adults who have 2-5 times of defecation per week 2. Those who are considered as appropriate for the study by the physician 3. Above 2, priority selective those who have high CAS scores in CAS-MT at screening and pre-ingestion

Exclusion criteria

Exclusion criteria: 1. Those who have the medical history or under the treatment of malignant tumor 2. Those who have the medical history or under the treatment of autoimmune disease 3. Those who have the medical history or under the treatment of inflammatory bowel disease 4. Those who are currently hospitalized 5. Those who use or take "Foods for Specified Health Uses" and "Foods with Functional Claims" in daily 6. Those who eat Natto, yogurt, and food and beverage including lactic acid bacteria in daily 7. Those who are smokers 8. Those who take anti-allergic drugs 9. Those who take laxative tablets 10. Those who are currently taking supplements 11. Those who are allergic to medicines and/or the test food related products 12. Those who are pregnant, breast-feeding, and plan to become a pregnant 13. Those who have been enrolled in other clinical trials within the last three months before the agreement to participate in this trial 14. Others considered as inappropriate for the study by the physician

Design outcomes

Primary

MeasureTime frame
1. The Japanese version of Constipation Assessment Scale MT version (CAS-MT) *Assess at 0 and 4 weeks after consuming

Secondary

MeasureTime frame
1. Subjective symptoms a. Bristol Stool Scale b. Bowel movement diary c. The Likert scale method * Above a and c, assess at 0 and 4 weeks after consuming * Above b, record when defecating 2. Immunity test T lymphocyte age, Immunological age, number of T cells, number of CD4+T cells / CD8+T cells ratio, number of naive T cells, naive T cells / memory T cells ratio, number of B cells, NK cells, and CD8+CD28+T cells, T-cell proliferation index, number of CD4+T cells, CD8+T cells and memory T cells *Assess at 0 and 4 weeks after consuming 3. Saliva test Salivary immunoglobulin A (sIgA) *Assess at 0 and 4 weeks after consuming 4. Blood test High-sensitive CRP, albumin, prealbumin *Assess at 0 and 4 weeks after consuming 5. Physical examination Muscle mass, grip strength *Assess at 0 and 4 weeks after consuming

Countries

Japan

Contacts

Public ContactNaoko SUZUKI

ORTHOMEDICO Inc. R&D Department

nao@orthomedico.jp03-3818-0610

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026